后装放疗剂量验证软件研究

目的 报道一套独立后装放疗剂量验证软件的实现方法和结果。方法 后装放疗剂量验证软件采用模块化结构设计,以Visual C++为开发平台,剂量计算算法采用AAPM TG 43报告推荐的公式。回顾性选择已完成治疗的宫颈癌患者6例,每例患者都使用了不同的施源器,用剂量体积直方图参数和γ通过率(0.1cm,5%)评估验证软件和计划系统剂量计算结果的偏差。结果 与计划系统剂量计算结果相比,验证软件剂量计算结果的γ通过率均>98%。靶区D100%和D90%的偏差最大值分别为0.29%和0.53%,危及器官D0.1cm³、D1cm³、D2cm³的偏差均<0.5%。结论 仅需极少的人机交互,该剂量验证软件能验证后装临床治疗计划剂量计算的准确性。

A study of an independent dose verification software for brachytherapy

Objective To report an implementation method and results of an independent brachytherapy dose verification software (DVS). Methods The DVS was developed based on Visual C++ and the modular structure design was adopted. The DICOM RT files exported from the treatment planning system (TPS) were automatically loaded into the DVS. The TG-43 formalism was employed for dose calculation. Six cervical cancer patients who underwent brachytherapy were retrospectively selected to test the DVS. Different applicators were utilized for each patient. Dosimetric parameters and γ analysis (0.1cm, 5%) were used to evaluate the dose difference between the DVS and the TPS. Results Compared with the TPS dose,the γ pass rates of the doses calculated by the DVS were higher than 98%. For CTV, the dosimetric differences were less than 0.29% and 0.53% for D100% and D90%. For bladder, rectum and sigmoid, the agreement of D0.1cm³, D1cm³and D2cm³ within a 0.5% level. Conclusion With minimal human-computer interactions, the DVS can verify the accuracy of dose calculated by TPS for brachytherapy.